Active trigger-point sites differ measurably from control tissue in local biochemistry, stiffness, and blood flow.

Three independent modalities (chemistry, stiffness, flow) report objective local abnormality, which defeats pure examiner-artifact accounts — but samples are small, definitions heterogeneous, and the biochemistry was elevated remotely too.

Microdialysis studies and imaging systematic reviews confirm that active sites exhibit objective local differences, including an acidic biochemical milieu and abnormal blood flow. This refutes the idea that trigger points are pure examiner artifacts. The strongest opposing consideration is that small, heterogeneous methodologies risk manufacturing apparent objectivity, and the findings (like ischemia) are equally compatible with conventional neuromuscular guarding.

Evidence from Shah et al. (VASO-E006) shows elevated pain- and inflammation-related mediators in a more acidic milieu at and near active trigger points, and a systematic imaging review (VASO-E007) finds that active and latent points differ from healthy tissue in stiffness and blood-flow parameters. These converging modalities support the existence of measurable local biochemical, mechanical, and hemodynamic differences at clinically identified sites. However, studies are small, heterogeneous in methods and definitions, and the biochemical changes were not strictly confined to the trigger point itself. The strongest opposing consideration is that such abnormalities could arise downstream of chronic neuromuscular guarding or more diffuse inflammatory processes, so they do not uniquely implicate a vascular-latch mechanism.

Shah et al. 2008 (VASO-E006) found acidic, mediator-rich fluid at active points, also elevated remotely; the audited Mazza et al. 2021 review (VASO-E007) concluded that imaging parameters can distinguish active and latent points from healthy tissue. Multiple modalities cut against a pure examiner-artifact story, but samples are small, methods heterogeneous, biochemical elevation is not purely local, and localization still inherits the palpation problem (VASO-C030). Strongest opposing consideration: ischemia and stiffness downstream of guarded skeletal muscle would produce the same chemical and Doppler picture, so these findings do not identify a vascular latch.

Two moderate records converge: E006 (Shah 2008 microdialysis — acidic, mediator-rich milieu at active points, though small-n and with mediators elevated at remote sites too, per the paper's own title) and E007 (a 2021 imaging systematic review of 33 studies finding active and latent points quantifiably distinguishable from healthy tissue — characterized second-hand from the critical report, not verified against full text). Multi-modal objective abnormality defeats pure examiner-artifact accounts. The strongest opposing consideration is that heterogeneous small studies with flexible trigger-point definitions inherit the localization problem documented under VASO-C030, and that guarding-induced compression by skeletal muscle would produce the same ischemic chemistry — the findings establish that something is there, not what it is.

Two independent modalities converge: E006 found an acidic, mediator-rich milieu at active trigger points, and E007 reports a systematic review concluding that biomechanical and blood-flow imaging parameters distinguish active and latent points from healthy tissue. Together these defeat the strongest examiner-artifact reading. The strongest opposing consideration is measurement quality: E006 had roughly nine volunteers and found mediator elevation remote from the points as well as near them, undercutting locality, while E007's characterization is second-hand from the critical report, spans heterogeneous techniques and definitions, and inherits the unblinded localization problem of C030. The findings establish that something objective is present without identifying its mechanism.

Three modalities (VASO-E006, VASO-E007) report objective local abnormality, defeating pure examiner-artifact accounts — but samples are small, definitions heterogeneous, and the biochemical elevations were not purely local.

Multiple independent modalities report objective local abnormality (VASO-E006, VASO-E007), defeating pure examiner-artifact accounts, though samples are small and definitions heterogeneous. Unchanged.

Multiple instrumented modalities report objective local abnormality (VASO-E006, VASO-E007), defeating pure examiner-artifact accounts, with small samples and heterogeneous definitions. Unchanged.

Multiple instrumented modalities report objective local abnormality (VASO-E006, VASO-E007), which defeats pure examiner-artifact accounts, though samples are small and definitions heterogeneous. Unchanged.

Multiple modalities report objective local abnormality (VASO-E006, VASO-E007), defeating pure examiner-artifact accounts, though samples are small and definitions heterogeneous. Unchanged.

Multiple instrumented modalities report objective local abnormality (VASO-E006, VASO-E007), defeating pure examiner-artifact accounts, though samples are small and definitions heterogeneous. Unchanged.

Multiple modalities report objective local abnormality (VASO-E006, VASO-E007), defeating pure examiner-artifact accounts, with small samples and heterogeneous definitions. Unchanged.

Multiple modalities report objective local abnormality (VASO-E006, VASO-E007), defeating pure examiner-artifact accounts, though samples are small and definitions heterogeneous. Unchanged.

Multiple independent modalities (microdialysis, ultrasound elastography, Doppler) show that active trigger points possess a more acidic, mediator-rich biochemical milieu and abnormal stiffness/flow parameters. The strongest limitation is the heterogeneity and small sample sizes of these studies, along with findings that biochemical mediators are also elevated remotely, complicating the strictly local "energy crisis" narrative.

Shah’s microdialysis work (VASO-E006) and the Mazza et al. imaging review (VASO-E007) report that active trigger points differ from control tissue in acidity, pain mediators, stiffness, and blood flow, which supports the existence of genuine local physiological abnormalities. These findings argue against a pure examiner-artifact account. The strongest opposing consideration is that the studies are small, heterogeneous, sometimes show mediator elevation at remote sites as well, and inherit all the localization and construct-validity concerns associated with palpation-based trigger-point identification.

VASO-E006 (Shah 2008) found pain mediators and acidity elevated at active trigger points, and VASO-E007 (Mazza 2021 systematic review, characterized second-hand) reports imaging parameters distinguishing active and latent points from healthy tissue, including flow abnormalities. Multiple modalities arguing in the same direction beat a pure artifact story. Strongest opposing consideration: Shah's elevations were also remote from the points, samples are small, methods heterogeneous, and until localization is blinded these "objective" findings inherit the reliability problem they are supposed to solve.

Multiple modalities point to objective local abnormality: active trigger-point regions show acidic, mediator-rich sampling including bradykinin, substance P, and CGRP (VASO-E006), and an imaging systematic review is characterized as finding active and latent points quantifiably distinguishable from healthy tissue (VASO-E007). The strongest opposing consideration is measurement inheritance: small heterogeneous studies, flexible trigger-point definitions, second-hand characterization of the review, and Shah's own remote-site elevations mean “instruments find the spot” can still import the localization problem identified in VASO-E011. Guarding-induced compression could also produce similar downstream ischemia and chemistry. The claim supports “something objective is there,” not the vascular-latch interpretation.

Two independent modalities converge: E006 found an acidic, mediator-rich milieu at active trigger points, and E007 reports a systematic review of 33 imaging studies concluding active and latent points are quantifiably distinguishable from healthy tissue on biomechanical and flow parameters. Together these defeat the strongest examiner-artifact reading. The strongest opposing considerations are internal to the records themselves: Shah's own title concedes elevation at sites remote from the points (nine volunteers), the imaging review is characterized second-hand from the critical report and spans heterogeneous techniques and trigger-point definitions, and every included study located its object by the unreliable palpation exam of C030. Objective difference is supported; its locality and specificity are not.

Multiple modalities report objective local abnormality (VASO-E006, VASO-E007), defeating pure examiner-artifact accounts, though samples are small and definitions heterogeneous. Unchanged.

Convergent instrumented abnormality across biochemistry, stiffness, and flow (VASO-E006, VASO-E007) defeats pure examiner-artifact accounts, though samples are small and definitions heterogeneous. Unchanged.

Multiple modalities, including microdialysis and imaging, report objective local differences in biochemistry, flow, and stiffness at active trigger points (VASO-E006, VASO-E007). The strongest opposing consideration is that these studies are small and heterogeneous, and the biochemical markers were also found elevated in remote tissues, challenging the assumption of a strictly focal lesion.

Microdialysis work (VASO-E006) shows elevations of pain- and inflammation-related mediators and lower pH at and around active trigger points, and the imaging review (VASO-E007) finds that active and latent points can be distinguished from healthy tissue on stiffness and blood-flow parameters. These converging lines support the claim that active sites differ measurably from control tissue in biochemistry, stiffness, and flow. Yet samples are small, techniques heterogeneous, mediator elevations are not strictly local, and palpation-based localization inherits the reliability issues detailed in VASO-E011. The strongest opposing consideration is that heterogeneous small studies with flexible definitions can produce apparent differences that partly reflect methodological artifacts rather than a consistent underlying lesion.

Shah et al. 2008 (VASO-E006) found pain-associated mediators and acidity elevated at active points, also remotely; Mazza et al. 2021 as audited (VASO-E007) concluded imaging can distinguish active and latent points from healthy tissue, with reproducibility caveats. Multiple independent modalities therefore point at local abnormality rather than pure examiner artifact. Strongest opposing consideration: small heterogeneous studies with palpation-defined sites inherit VASO-C030's localization problem, Shah's remote elevations weaken a strictly focal-ischemia reading, and the Mazza characterization in this file is second-hand from the critical report.

Two independent modalities converge: microdialysis found an acidic, mediator-rich milieu at active points (VASO-E006), and a 33-study imaging systematic review found active and latent points quantifiably distinguishable from healthy tissue on stiffness and flow (VASO-E007). Against this: the biochemical study was small (roughly nine volunteers) with mediators elevated remotely as well as locally, the imaging literature is heterogeneous in technique and definition, the review's characterization is second-hand from the critical report, and all of it inherits the localization problem of VASO-E011 — instruments can only find the spot where palpation points. The findings are mechanism-neutral: guarding with downstream ischemia predicts the same chemistry. As an existence claim for objective local abnormality, provisionally supported.

Two independent modalities report objective differences: E006 (microdialysis finding an acidic, mediator-rich milieu at active points) and E007 (a systematic review of 33 imaging studies concluding active and latent points are quantifiably distinguishable from healthy tissue on biomechanical and blood-flow parameters). That convergence is real and is the main thing pure examiner-artifact accounts must answer. But the evidentiary quality is modest: E006 had nine volunteers and, per its own title, found mediators elevated remote from the points as well as near them, and E007's characterization is second-hand from the critical report with the review's full text unchecked. The strongest opposing consideration is circularity: every included study localized its object by the palpation method E011 found unreliable, so "instruments find the spot" partly inherits the measurement problem it is invoked to solve.

Multiple independent measurement modalities report objective local differences, and a 2021 systematic review of imaging studies concluded active and latent points are quantifiably distinguishable from healthy tissue — but samples are small, methods heterogeneous, and the biochemical study found mediator elevation remote from the points too.

Multiple independent imaging and biochemical modalities demonstrate that palpated active trigger points differ measurably from surrounding muscle tissue, showing elevated neuropeptides and acidity on microdialysis (Shah 2008), increased stiff-area dimensions on sonoelastography, and altered pulsatility on Doppler (Ballyns 2011, Mazza 2021). The strongest opposing consideration is that Doppler resistivity index does not differ, blood flow changes do not cleanly classify individual sites due to high variance, and neuropeptide elevations are partly systemic.

Multiple independent physical modalities confirm measurable differences at active trigger points: microdialysis reveals elevated inflammatory and nociceptive mediators (VASO-E006), vibration sonoelastography shows increased stiff areas (VASO-E023), and Doppler ultrasound identifies elevated pulsatility indices (VASO-E022, VASO-E007). The strongest opposing consideration is that these differences are relative and graded rather than binary; for instance, resistivity indices do not differ (VASO-E024), and retrograde diastolic flow is observed in over 30% of normal control sites (VASO-E022, VASO-E026).

Active trigger points demonstrate distinct physical and chemical parameters compared to control sites: microdialysis shows elevated inflammatory mediators and lower pH (Shah et al. 2008), sonoelastography documents larger stiff areas (Ballyns et al. 2011), and systematic reviews confirm measurable imaging differences (Mazza et al. 2021). The strongest opposing consideration is that Doppler resistivity index does not differ between sites, and retrograde diastolic flow is present in nearly a third of normal sites, indicating that hemodynamic differentiation is graded rather than absolute.

The claim is supported across all three modalities: biochemical elevation (VASO-E006), robustly classified stiffness differences with blinded sonographers (VASO-E023, AUC 0.8–0.9), and group-level flow differences (VASO-E022), corroborated at review level (VASO-E007). The strongest opposing consideration is that the blood-flow component is weak — resistivity index shows no difference (VASO-E024/E025) and there is no pain-free control group (VASO-E026), so the contrast is a gradient within symptomatic muscle, not a categorical marker.

Active trigger-point sites differ measurably from comparison tissue in biochemistry (VASO-E006, elevated inflammatory mediators), stiffness (VASO-E023: graded areas 0.57/0.36/0.17 cm² with blinded sonographers, AUC 0.9), and group-level blood flow (VASO-E031... specifically VASO-C031/C032 via VASO-E022), with systematic-review support (VASO-E007). The strongest opposing considerations temper rather than overturn: flow indices do not classify individual sites and the resistivity index is null (VASO-E025), and every comparison is within symptomatic patients with no pain-free control group (VASO-E026), so the "difference" may partly reflect spillover within already-abnormal muscle.

VASO-E006 (biochemical milieu), VASO-E007 (systematic review), and VASO-E023 (blinded sonoelastography, AUC 0.8–0.9) give the claim real instrumented support. The strongest opposing considerations are recorded against it: the Doppler signature is graded and partial (RI null, PI a poor classifier — VASO-E024/E025), all comparisons are within symptomatic patients without a pain-free control (VASO-E026), and the Shah lineage is not independent. Measurable difference survives at group level; the mechanism does not follow.

VASO-E006 supports biochemical differences, while VASO-E023 provides instrumented stiffness separation and VASO-E022 reports a group-level pulsatility difference. These collectively support measurable differences across all three named domains. The strongest opposing consideration is that much of the evidence comes from one NIH lineage, biochemical elevations were also remote from the points, and the Doppler signal was partial: resistivity was null, pulsatility classified poorly, and no pain-free control group was included.

VASO-E006 supports biochemical differences, VASO-E023 supports a graded stiffness difference, and VASO-E022 supports a group-level pulsatility difference near active sites. The imaging review in VASO-E007 provides broader but second-hand support across heterogeneous methods. The strongest opposing consideration is VASO-E024–E026: resistivity was null, flow indices classified individual sites poorly, and comparison sites came from symptomatic patients, so the blood-flow component is partial rather than categorical.

VASO-E006 supports biochemical differences, VASO-E023 supports graded stiffness differences, and VASO-E022 supports a group-level pulsatility difference near active sites. Thus all three measurement domains named in the claim have positive evidence. The strongest opposing consideration is that blood-flow indices were poor individual classifiers, resistivity index was null, controls came from symptomatic muscle, and much of the evidence comes from one research lineage.

Shah microdialysis shows elevated pain/inflammatory mediators in a more acidic milieu; Ballyns vibration elastography yields graded stiff-area (active > latent > normal) with good ROC separation; Doppler shows higher pulsatility and more frequent retrograde flow near active sites. Resistivity index does not differ and pulsatility is a poor individual-site classifier; all comparisons are within symptomatic muscle. Strongest opposing consideration is the lack of pain-free controls and the conduit-scale vessels imaged.

Shah microdialysis shows elevated pain/inflammation mediators and acidity at active sites (E006). Mazza 2021 systematic review and Ballyns 2011 vibration elastography plus Doppler confirm quantifiable differences in stiff area and at least one flow index (E007, E022, E023). Nulls and qualifiers exist (RI no difference, PI poor classifier, 31 % retrograde flow at palpably normal sites, no pain-free controls—E024–E026), so the differences are graded and group-level rather than categorical biomarkers. Strongest opposing consideration is residual dependence on palpation-defined site selection.

Shah microdialysis (acidic mediator-rich milieu), Mazza imaging review, Ballyns vibration elastography (graded stiff areas active > latent > normal, ROC-capable), and Ballyns Doppler (higher PI, more retrograde flow near active sites) establish measurable differences. Qualifiers: biochemistry not purely local; RI null; PI poor as individual classifier; no pain-free controls; vessels conduit-scale. Strongest opposing consideration: differences confirm something is wrong at the site but do not identify latched microvessels.

Three lines converge: microdialysis showing an acidic, mediator-rich milieu at active points (VASO-E006), a systematic imaging review reporting biomechanical and flow parameters distinguishing active and latent points from healthy tissue (VASO-E007, second-hand), and Ballyns' blinded sonoelastography with a clean active > latent > normal stiff-area gradient and AUC 0.9 (VASO-E023). Blinding of the sonographers is a real strength over the palpation-only literature. The strongest opposing considerations are circularity (sites were defined by palpation, so the contrast presupposes the classification), the absence of any pain-free control group (VASO-E026), the null resistivity index and poor per-site classification by Doppler (VASO-E024, VASO-E025), Shah's finding of elevated mediators remote from the points as well as near them, and the shared NIH lineage of Shah and Ballyns. Group-level differences survive; "a marker" does not.

Three modalities point the same way: acidic mediator-rich milieu (VASO-E006), graded stiff-area differences with blinded sonographers and AUC 0.8–0.9 (VASO-E023), and higher pulsatility with more frequent retrograde flow (VASO-E022), with a systematic review reporting the same residue (VASO-E007). Four things hold the verdict below well_supported: Shah, Sikdar and Ballyns are one NIH lineage rather than independent replications; VASO-E007's characterization is second-hand and unchecked; sites are defined by the palpation whose reliability VASO-E011 disputes, making the contrast partly circular; and the flow findings are group-level only, with a null resistivity index (VASO-E024), poor per-site classification (VASO-E025) and no pain-free controls (VASO-E026).

Three independent-ish strands converge: acidic, mediator-rich microdialysis chemistry at active points (VASO-E006), a systematic review of 33 imaging studies finding biomechanical and blood-flow parameters can distinguish active and latent points from healthy tissue (VASO-E007), and blinded vibration sonoelastography separating active, latent and normal sites with AUC 0.8–0.9 plus a group-level pulsatility difference (VASO-E022, VASO-E023). The strongest opposing considerations are serious but do not overturn the claim as stated: sites are selected by palpation, so the contrast presupposes the classification; Ballyns had no pain-free control group and its "normal" sites sat in symptomatic muscle (VASO-E026); the Doppler indices do not classify individual sites and resistivity index shows no difference at all (VASO-E024, VASO-E025); and Shah's mediators were elevated remote from the points as well as at them.

VASO-E006 (moderate): bradykinin, substance P and CGRP elevated in a more acidic milieu at active trigger points — in about nine volunteers, and, per the paper's own title, at sites remote from as well as near the points. VASO-E007 (moderate): a systematic review of 33 imaging studies finds biomechanical and blood-flow parameters can distinguish active and latent points from healthy tissue, with reproducibility caveats; this characterization is second-hand from the critical report.

Biochemistry: microdialysis in about nine volunteers found an acidic, mediator-rich milieu at active points, elevated remotely too (VASO-E006). Stiffness: blinded vibration sonoelastography in 44 patients separates active, latent and normal sites in a graded way with AUC 0.9 (VASO-E023, moderate) — the claim's strongest component. Blood flow: pulsatility index higher and retrograde flow more frequent near active sites at group level (VASO-E022), but the resistivity index is null, the pulsatility index cannot classify sites, and blood-flow measures 'did not perform well as classifiers' (VASO-E024, VASO-E025); all comparisons sit within symptomatic muscle with no pain-free controls (VASO-E026). The 2021 imaging review (VASO-E007) is characterized only second-hand. Sites were selected by palpation and both primaries share one NIH lineage.

Supported on three axes: acidic, mediator-rich milieu (VASO-E006), blinded-sonographer stiffness gradient (VASO-E023), higher pulsatility index and more frequent retrograde flow near active sites (VASO-E022), and a second-hand systematic review (VASO-E007). Qualified by the same source: Doppler indices do not classify sites and the resistivity index is null (VASO-E025), and no pain-free control group exists (VASO-E026). The essay's Doppler-as-footprint reading (VASO-E042) omits the nulls and is interpretation. Records come from one NIH lineage.

Supported by VASO-E006, E007 (second-hand), E022 and E023; qualified by E024, E025 and E026 (null resistivity index, pulsatility index that cannot classify sites, no pain-free controls); E042 context; E050 and E051 are weak restatements from an unverified source. The stiffness component is blinded and graded; the flow component is partial; the chemistry is not clearly local.

VASO-E006 (chemistry: acidic, mediator-rich milieu in about nine volunteers, elevated at remote sites too), VASO-E007 (imaging review, characterized second-hand), VASO-E023 (blinded sonoelastography: graded stiff area, AUC 0.9) and VASO-E022 (higher pulsatility index near active points) support; VASO-E025 and VASO-E026 qualify (indices do not classify sites; no pain-free controls); VASO-E042 is context. VASO-E050 and VASO-E051 rest on an unread source and are treated as absent. Stiffness is well shown; flow differences are partial; chemistry is small.

Acidic, mediator-rich fluid at active points, elevated remotely as well (VASO-E006); blinded-sonographer graded stiffness in the trapezius (VASO-E023); a group-level pulsatility difference (VASO-E022) whose indices cannot classify sites (VASO-E025) and sit inside symptomatic muscle with no pain-free controls (VASO-E026); a second-hand systematic review (VASO-E007). A second laboratory reproduces the stiffness gradient in the calf — active points stiffer relative to surrounding muscle than latent ones (VASO-E071), larger (VASO-E070), more painful (VASO-E069), cleared less often after one round (VASO-E072) — but as active-versus-latent within symptomatic runners, with no control tissue, no Doppler and no biochemistry, which is why those records are context and qualifier. Essay restatements (VASO-E042, VASO-E050, VASO-E051) add no weight.

Biochemistry: acidic, mediator-rich milieu at active points, but elevated remotely too, in about nine volunteers (VASO-E006). Stiffness: blinded graded stiff area in the trapezius (VASO-E023) and active/latent differences in the calf by a second method (VASO-E069, VASO-E070, VASO-E071, VASO-E072 — context and qualifier, since there is no control tissue). Flow: higher pulsatility near active points (VASO-E022) but a null resistivity index, indices that cannot classify sites (VASO-E025) and no pain-free controls (VASO-E026). A systematic review characterized second-hand (VASO-E007) and essay restatements (VASO-E042; VASO-E050, VASO-E051 from an unread source) add little.

Supported by microdialysis (VASO-E006), the imaging review as characterized second-hand (VASO-E007), and Ballyns 2011's blinded stiffness gradient (VASO-E023) and group-level Doppler difference (VASO-E022); qualified by the same source's no-pain-free-controls limitation (VASO-E026) and non-classifying indices (VASO-E025), and by Landfald's active-versus-latent comparison having no control tissue (VASO-E070). Landfald's pain, stiffness-ratio and first-round disappearance figures are context (VASO-E068, VASO-E069, VASO-E071, VASO-E072). Essay restatements (VASO-E042, VASO-E050, VASO-E051) carry no weight. Measurable differences exist; the vascular component is partial.

Biochemistry: an acidic, mediator-rich milieu at active points, elevated also at remote sites (VASO-E006, moderate). Stiffness and flow: a systematic imaging review, characterized second-hand, reports measures distinguishing points from healthy tissue (VASO-E007, moderate); the trapezius graded stiff-area figures now sit on the child claims VASO-C182 and VASO-C183 with their record provisional, so this claim's stiffness component rests on VASO-E007 and on calf active/latent differences held as context and qualifier (VASO-E069, VASO-E070, VASO-E071; VASO-E068 classification; VASO-E072 first-round disappearance), none with control tissue. Flow: a group-level pulsatility difference (VASO-E022) qualified by no pain-free controls and indices that cannot classify sites (VASO-E026, VASO-E025). VASO-E042 is the essay's interpretation; VASO-E050 and VASO-E051 come from an unread source and are treated as absent.

Group-level differences are supported on three axes: biochemistry (VASO-E006), stiffness by blinded vibration sonoelastography with ROC separation of site classes (VASO-E087, VASO-E090, VASO-E091, VASO-E094, VASO-E096, VASO-E099) and Doppler pulsatility (VASO-E022), with a second-hand systematic review (VASO-E007). The same source qualifies: no pain-free controls (VASO-E026), flow indices that cannot classify sites (VASO-E025), sites selected by palpation, one vibration frequency, one NIH lineage. Landfald's calf differences are active against latent with no control tissue (VASO-E069, VASO-E071, VASO-E072 context; VASO-E070 qualifies). VASO-E042, VASO-E050 and VASO-E051 are essay restatements, the last two from an unread source.

Supported by biochemistry (VASO-E006), a second-hand review (VASO-E007), Doppler (VASO-E022), and the trapezius stiff-area gradient — active and latent areas above normal (VASO-E091), the normal-site value (VASO-E090), classifiers (VASO-E096, VASO-E099) and overall ROC separation (VASO-E100, VASO-E102), with VASO-E088, VASO-E097, VASO-E101 and VASO-E103 as context. Qualified by no pain-free controls (VASO-E026), non-classifying flow indices (VASO-E025) and the calf active-versus-latent comparison lacking control tissue (VASO-E070; VASO-E068, VASO-E069, VASO-E071, VASO-E072 context). VASO-E042 is interpretation; VASO-E050 and VASO-E051 rest on an unread source.

Biochemistry from Shah 2008 in about nine volunteers, elevated at remote as well as near sites (VASO-E006); the Mazza review, second-hand (VASO-E007); Ballyns 2011's group-level Doppler difference (VASO-E022) and blinded vibration-elastography stiff-area gradient (VASO-E087, VASO-E090, VASO-E091, VASO-E092, VASO-E096, VASO-E099, VASO-E100, VASO-E102), capped by no pain-free controls (VASO-E026) and flow indices that cannot classify sites (VASO-E025); Landfald 2025's active-versus-latent differences in the calf as context and qualifier (VASO-E068, VASO-E069, VASO-E070, VASO-E071, VASO-E072). The second-essay restatements (VASO-E050, VASO-E051) rest on an unread source and are treated as absent. Group-level differences are real; every comparison sits inside symptomatic muscle at palpation-selected sites.

Chemistry: an acidic, mediator-rich milieu at active points, about nine volunteers, elevated at remote sites too (VASO-E006). Imaging: a 33-study review, characterized second-hand, reports stiffness and flow differences from healthy tissue (VASO-E007); Ballyns 2011 gives a group-level pulsatility difference (VASO-E022) and a graded stiff-area difference with active and latent above normal (VASO-E091, VASO-E090), classifiers for active versus normal (VASO-E096) and active versus latent (VASO-E099), and overall ROC separation (VASO-E100, VASO-E102), with the abstract's ROC listing as context (VASO-E101, VASO-E103). Qualified by the same source — indices that cannot classify sites (VASO-E025), no pain-free controls (VASO-E026) — and paralleled in the calf by active/latent differences within symptomatic runners with no control tissue (VASO-E068, VASO-E069, VASO-E070, VASO-E071, VASO-E072, context and qualifier). Second-essay restatements (VASO-E050, VASO-E051) and the essay's Doppler gloss (VASO-E042) carry no weight.

Shah 2008 (VASO-E006) gives acidic, mediator-rich fluid at active points, elevated remote from them as well; the Mazza review, second-hand (VASO-E007), gives group-level stiffness and flow differences. Ballyns 2011 supplies the Doppler difference (VASO-E022) and the graded stiff-area finding with ROC separation (VASO-E091, VASO-E092, VASO-E096, VASO-E099, VASO-E100, VASO-E102; VASO-E087, VASO-E090), capped by its own qualifiers: no pain-free controls (VASO-E026), flow indices that cannot classify sites (VASO-E025); VASO-E088, VASO-E097, VASO-E101, VASO-E103 are context. Landfald 2025 adds active/latent differences in a second muscle without control tissue (VASO-E069, VASO-E071, VASO-E072 context; VASO-E070 qualifies; VASO-E068 context). Essay restatements (VASO-E042) and records from an unread source (VASO-E050, VASO-E051) carry no weight. Group-level differences are real; individual-site classification is not.

Active trigger points consistently differ from control tissue across multiple objective modalities: microdialysis shows elevated inflammatory mediators and acidic pH (VASO-E006; Shah 2008), sonoelastography demonstrates larger stiff areas across multiple independent labs (VASO-E007, VASO-E068, VASO-E087, VASO-E091), and Doppler ultrasound reveals higher pulsatility indices and retrograde diastolic flow (VASO-E022; Ballyns 2011). The strongest opposing consideration is that Doppler resistivity index does not differ between sites (VASO-E024), flow measures fail as individual site classifiers (VASO-E025), and comparator sites in primary imaging studies came from symptomatic patients rather than pain-free controls (VASO-E026).

Blinded sonographers distinguished active, latent and palpably normal sites on elastography with AUCs of 0.8-0.9 (E087-E099), microdialysis found pain and inflammation mediators elevated at active sites (E006), Doppler showed group-level flow differences (E022), and a second laboratory, muscle and method reproduced the active/latent stiffness and size gradient (E070, E071, E085, E086). The strongest opposing considerations are that the differences are graded rather than categorical — a null resistivity index, 31% retrograde flow at normal sites, and a pulsatility index that classifies poorly (E024, E025, E026) — and that all comparators are within symptomatic muscle, while the biochemical elevation is not purely local.

VASO-E006 supports biochemical differences, while the admitted Ballyns records support larger stiff areas and group-level Doppler differences at active sites; VASO-E007 reports a broader imaging-review residue in the same direction. The finding is therefore supported across the three named measurement domains, although not with equally strong or independent evidence. The strongest opposing consideration is that much of the primary evidence comes from one NIH lineage, uses palpation-selected sites, lacks pain-free controls, and shows blood-flow overlap rather than a diagnostic vascular signature.

Shah microdialysis shows elevated acidic pain mediators (E006); Ballyns vibration elastography and Doppler show larger stiff areas and higher pulsatility/retrograde flow at active sites (E022, E087–E099 series); Mazza review summarizes quantifiable imaging differences (E007). Differences are graded, RI null, classifiers imperfect, no pain-free controls, shared NIH lineage. Strongest opposing consideration is that measurable difference does not identify the tissue element (fiber, fascia, vessel, or guard).

Stiffness is the best-supported component. Blinded sonographers found stiff areas of 0.57, 0.36 and 0.17 cm² at active, latent and palpably normal sites (P < .01; E087, E089, E090–E092), and an independent group found active gastrocnemius points larger and stiffer than latent ones, though without normal controls (E070, E071). Blood flow differs only at group level on one index, a higher pulsatility index near active sites (E022), with no resistivity-index difference and poor classification of individual sites (E024, E025). Biochemistry rests on one small microdialysis study whose own title reports elevation remote from the points as well as near them (E006), and the imaging review's summary is second-hand (E007). Strongest opposing consideration: apart from the stiffness parallel, everything comes from one NIH lineage whose "control" sites sit in symptomatic muscle with no pain-free group (E026). The size and locality of the blood-flow and biochemical differences are therefore not established.

Acidic, mediator-rich fluid at active points (VASO-E006; about nine subjects; also at remote sites). Blinded vibration sonoelastography separates active, latent and normal sites (VASO-E087, VASO-E090, VASO-E091, VASO-E096, VASO-E099, VASO-E100, VASO-E102). There is a group-level Doppler difference (VASO-E022) and a second-hand review (VASO-E007). All are capped by the absence of pain-free controls (VASO-E026) and by flow indices that do not classify sites (VASO-E025). The calf findings (VASO-E071, VASO-E072) are context.